These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39134586)

  • 1. Gut microbiome perturbation and its correlation with tylosin pharmacokinetics in healthy and infected pigs.
    Lee EB; Lee GY; Hossain MA; Awji EG; Park SC
    Sci Rep; 2024 Aug; 14(1):18670. PubMed ID: 39134586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics of tilmicosin in healthy pigs and pigs experimentally infected with
    Xiong J; Zhu Q; Yang S; Zhao Y; Cui L; Zhuang F; Qiu Y; Cao J
    N Z Vet J; 2019 Sep; 67(5):257-263. PubMed ID: 31208293
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing tylosin dosage for co-infection of
    Lee EB; Abbas MA; Park J; Tassew DD; Park SC
    Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro antibacterial properties of tilmicosin against Australian isolates of Pasteurella multocida and Actinobacillus pleuropneumoniae from pigs.
    Blackall PJ; Asakawa T; Graydon RJ; White M; Adamson M; Wade LK; Lowe LB
    Aust Vet J; 1995 Jan; 72(1):35-6. PubMed ID: 8787526
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
    Rose M; Menge M; Bohland C; Zschiesche E; Wilhelm C; Kilp S; Metz W; Allan M; Röpke R; Nürnberger M
    J Vet Pharmacol Ther; 2013 Apr; 36(2):140-53. PubMed ID: 22500881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tilmicosin enteric granules and premix to pigs: Antimicrobial susceptibility testing and comparative pharmacokinetics.
    Xiong J; Zhu Q; Zhao Y; Yang S; Cao J; Qiu Y
    J Vet Pharmacol Ther; 2019 May; 42(3):336-345. PubMed ID: 30801755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
    Blondeau JM; Fitch SD
    PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine.
    Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K
    J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs.
    Huang L; Zhang H; Li M; Ahmad I; Wang Y; Yuan Z
    BMC Vet Res; 2018 Oct; 14(1):319. PubMed ID: 30355326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the Antibiotics Growth Promoter Tylosin on Swine Gut Microbiota.
    Kim J; Guevarra RB; Nguyen SG; Lee JH; Jeong DK; Unno T
    J Microbiol Biotechnol; 2016 May; 26(5):876-82. PubMed ID: 26869601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
    Shryock TR; Staples JM; DeRosa DC
    J Vet Diagn Invest; 2002 Sep; 14(5):389-95. PubMed ID: 12296390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
    Moore GM; Basson RP; Tonkinson LV
    Am J Vet Res; 1996 Feb; 57(2):224-8. PubMed ID: 8633813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gamithromycin in swine: Pharmacokinetics and clinical evaluation against swine respiratory disease.
    Hamel D; Richard-Mazet A; Voisin F; Böhne I; Fraisse F; Rauh R; Huang R; Kellermann M; Letendre L; Dumont P; Rehbein S
    Vet Med Sci; 2021 Mar; 7(2):455-464. PubMed ID: 33058489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tilmicosin- and florfenicol-loaded hydrogenated castor oil-solid lipid nanoparticles to pigs: Combined antibacterial activities and pharmacokinetics.
    Ling Z; Yonghong L; Junfeng L; Li Z; Xianqiang L
    J Vet Pharmacol Ther; 2018 Apr; 41(2):307-313. PubMed ID: 29139136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs.
    Dayao D; Gibson JS; Blackall PJ; Turni C
    Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
    Dorey L; Pelligand L; Lees P
    BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media.
    Dorey L; Hobson S; Lees P
    Res Vet Sci; 2017 Apr; 111():43-48. PubMed ID: 27940285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Pasteurella multocida and Salmonella choleraesuis isolates from pigs.
    Raemdonck DL; Tanner AC; Tolling ST; Michener SL
    Vet Rec; 1994 Jan; 134(1):5-7. PubMed ID: 8128570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pigs experimentally infected with Mycoplasma hyopneumoniae, Pasteurella multocida, and Actinobacillus pleuropneumoniae with various antibiotics.
    Stipkovits L; Miller D; Glavits R; Fodor L; Burch D
    Can J Vet Res; 2001 Oct; 65(4):213-22. PubMed ID: 11768127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.